Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is expected to be announcing its Q4 2024 earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.04). On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Milestone Pharmaceuticals Stock Up 5.2 %
Shares of MIST stock traded up $0.10 during trading hours on Thursday, hitting $2.03. 2,363,829 shares of the company were exchanged, compared to its average volume of 379,786. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The business's 50-day simple moving average is $2.02 and its two-hundred day simple moving average is $1.79. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75. The stock has a market capitalization of $108.26 million, a price-to-earnings ratio of -2.51 and a beta of 1.83.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, February 28th.
Read Our Latest Analysis on MIST
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
